

13. (New) A method of treatment according to claim 12, wherein alosetron is in the form of its hydrochloride.

14. (New) A method of treatment according to claim 11, wherein the 5-HT₃ receptor antagonist is selected from granisetron, azasetron, tropisetron, ramosetron, ondansetron, lerisetron, (R) zacopride, ciansetron, itasetron, indisetron or dolasetron.

15. (New) A method of treatment of alternating constipation/diarrhea IBS which comprises administering an effective amount of a 5-HT₃ receptor antagonist or a pharmaceutically acceptable derivative thereof.

16. (New) A method of treatment according to claim 15, wherein the 5-HT₃ receptor antagonist is alosetron or a pharmaceutically acceptable derivative thereof.

17. (New) A method of treatment according to claim 16, wherein alosetron is in the form of its hydrochloride.

18. (New) A method of treatment according to claim 15, wherein the 5-HT₃ receptor antagonist is selected from granisetron, azasetron, tropisetron, ramosetron, ondansetron, lerisetron, (R) zacopride, ciansetron, itasetron, indisetron or dolasetron.